Tuesday, October 05, 2021 11:57:09 PM
Will we see Altria return? How much cash would they have to put up to regain exclusive license rights? They previously got a steal of a deal.
Altria owns 16.67% of Lexaria Nicotine and one seat of its board in connection with Altria's funding of Lexaria's nicotine research & development (R&D) program in 2019, while Lexaria owns the remaining 83.33% stake.
The company, which specializes in innovative drug delivery platforms, said Altria now has non-exclusive license rights to use DehydraTECHTM drug delivery technology for both the US and worldwide markets under a predefined royalty structure payable to Lexaria Nicotine.
Altria owns 16.67% of Lexaria Nicotine and one seat of its board in connection with Altria's funding of Lexaria's nicotine research & development (R&D) program in 2019, while Lexaria owns the remaining 83.33% stake.
The company, which specializes in innovative drug delivery platforms, said Altria now has non-exclusive license rights to use DehydraTECHTM drug delivery technology for both the US and worldwide markets under a predefined royalty structure payable to Lexaria Nicotine.
Recent LEXX News
- Lexaria to Begin New Human Clinical Study in GLP-1 • ACCESS Newswire • 04/01/2026 01:20:00 PM
- Lexaria's Robust Patent Portfolio Continues to Grow • ACCESS Newswire • 03/26/2026 01:20:00 PM
- Lexaria's Oral GLP-1 Drug Strategy Validated by Industry • ACCESS Newswire • 03/24/2026 01:15:00 PM
- Lexaria Announces New R&D Plans for 2026 • ACCESS Newswire • 03/04/2026 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:40 PM
- Lexaria Announces Positive Final Results From Human Pilot Study #5 • ACCESS Newswire • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 06:51:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/28/2026 06:33:53 PM
- Lexaria Awarded Six Additional Patents • ACCESS Newswire • 01/22/2026 02:20:00 PM
- 5 Assets Securing the 2026 Biological Choke Point • GlobeNewswire Inc. • 01/21/2026 02:55:00 PM
- Lexaria Releases Annual Letter from the CEO • ACCESS Newswire • 01/12/2026 02:10:00 PM
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/30/2025 02:20:00 PM
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 • ACCESS Newswire • 12/23/2025 02:29:00 PM
- Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/16/2025 09:00:00 PM
- Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 12/15/2025 01:00:00 PM
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended • ACCESS Newswire • 11/12/2025 02:10:00 PM
- Lexaria Bioscience Corp. Provides Strategic Update • ACCESS Newswire • 10/09/2025 01:20:00 PM
- Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/29/2025 08:30:00 PM
- Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • ACCESS Newswire • 09/26/2025 12:00:00 PM
- Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone • IH Market News • 08/14/2025 02:36:15 PM
